Ebola – the industry's response in antivirals
This article was originally published in Scrip
Executive Summary
The unprecedented scale of the Ebola epidemic in West Africa has prompted a similarly unprecedented interest in the response from the pharma and biotech industries to develop treatments and vaccines against the virus.